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SUMMARY
Objectives: Thrombospondins, which are known to interact with the a2d subunit of
voltage-sensitive calcium channels to stimulate the formation of excitatory synapses,
have recently been implicated in the process of epileptogenesis. No studies have been
so far performed on thrombospondins in models of absence epilepsy. We examined
whether expression of the gene encoding for thrombospondin-1 was altered in the
brain ofWAG/Rij rats, whichmodel absence epilepsy in humans. In addition, we exam-
ined the frequency of genetic variants of THBS1 in a large cohort of children affected by
idiopathic/genetic generalized epilepsies (IGE/GGEs).
Methods: Wemeasured the transcripts of thrombospondin-1 and a2d subunit, and pro-
tein levels of a2d, Rab3A, and the vesicular glutamate transporter, VGLUT1, in the
somatosensory cortex and ventrobasal thalamus of presymptomatic and symptomatic
WAG/Rij rats and in two control strains by real-time polymerase chain reaction (PCR)
and immunoblotting. We examined the genetic variants of THBS1 and CACNA2D1 in
two independent cohorts of patients affected by IGE/GGE recruited through the
Genetic Commission of the Italian League Against Epilepsy (LICE) and the EuroEPI-
NOMICS-CoGIE Consortium.
Results: Thrombospondin-1 messenger RNA (mRNA) levels were largely reduced in
the ventrobasal thalamus of both presymptomatic and symptomatic WAG/Rij rats,
whereas levels in the somatosensory cortex were unchanged. VGLUT1 protein levels
were also reduced in the ventrobasal thalamus of WAG/Rij rats. Genetic variants of
THBS1 were significantly more frequent in patients affected by IGE/GGE than in
nonepileptic controls, whereas the frequency ofCACNA2D1was unchanged.
Significance: These findings suggest that thrombospondin-1 may have a role in the
pathogenesis of IGE/GGEs.
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Absence epilepsy is a nonconvulsive type of epilepsy
characterized by brief periods of unresponsiveness associ-
ated with typical spike-and-wave discharges (SWDs) on
electroencephalography (EEG). SWDs are generated
within a corticothalamocortical network formed by highly
excitable neurons in the subgranular layer of the facial
region of the somatosensory cortex interconnected with
neurons of the reticular and ventrobasal thalamic nuclei.1,2
T-type voltage-sensitive Ca2+ channels (VSCCs) are criti-
cally involved in the generation of SWDs, as demonstrated
by the ability of the T-channel blocker, ethosuximide, to
normalize the activity of highly excitable cortical neurons
and to reduce burst firing of reticular and ventrobasal
thalamic neurons.3,4
A growing body of evidence suggests a potential role
for the a2d subunit of VSCCs in the pathophysiology of
nonconvulsive epilepsy. The mutant mouse ducky, which
carries a mutation for the gene encoding for the a2d-2 sub-
unit, is characterized by absence seizures and ataxia. In
addition, gabapentin and pregabalin, which bind to and
negatively modulate a2d-1 and a2d-2 proteins, may precip-
itate absence seizures in experimental animal models and
humans.5,6 The a2d subunit is known to regulate traffick-
ing, current amplitude, and activation/inactivation kinetics
of high-voltage activated VSCCs (e.g., L-, N-, and P/Q-
type VSSCs).7 The role of a2d subunit in the regulation of
T-type channels is less clear. Formation of a multimolecu-
lar complex between the a1 subunit of T channels and aux-
iliary subunits (a2d, b, and c subunits) has not yet been
demonstrated. However, there is evidence that expression
of the a2d subunit increases plasma membrane localization
and current density of T channels8–10 (see also Lacinova
et al.,11 for contrasting data). These findings are difficult
to reconcile with the evidence that genetic deletion or
pharmacologic blockade of the a2d subunit causes absence
seizures (see above), unless the function of the a2d subunit
is not restricted to the modulation of VSCCs. Of interest,
a2d-1 has been identified as a high affinity receptor
for thrombospondins,12 which, in the central nervous
system (CNS), are secreted from astrocytes and promote
synaptic formation under physiologic and pathologic
conditions.13,14 The interaction between the epidermal
growth factor–like domains of thrombospondins and a2d-1
mediates the effect of thrombospondins on synaptic forma-
tion. Of interest, the a2d ligand, gabapentin, inhibits the
induction of excitatory synaptic formation by throm-
bospondins.12 This stimulates interest for the study of
thrombospondins in models of absence epilepsy.
We used WAG/Rij rats, which develop spontaneous gen-
eralized bilateral symmetrical SWDs associated with
absence-like behavior after 2–3 months of age.15,16 SWDs
in symptomatic WAG/Rij rats are reduced by classical
antiabsence drugs, such as ethosuximide and valproate, and
are increased by drugs that aggravate absence seizures in
humans, such as phenytoin, carbamazepine, tiagabine, and
vigabatrin.17–19 This makes WAG/Rij rats a valuable model
for the study of human absence epilepsy.
We now report that the transcript of thrombospondin-1
was largely reduced in the ventrobasal thalamus of WAG/
Rij rats, both in the presymptomatic and symptomatic age,
as compared to nonepileptic controls. We then examined
the variants of THBS1 and CACNA2D1 in a cohort of
patients with idiopathic/genetic generalized epilepsy (IGE/
GGE) and found that variants in THBS1 but not in CAC-
NA2D1 were enriched in patients respect to control popula-
tion. These findings support a potential role for
thrombospondins in epileptogenesis and raise the interest-
ing possibility that changes in the expression and/or bio-
logic function of thrombospondin-1 contributes to the
pathogenesis of absence epilepsy.
Methods
Animals
We used male WAG/Rij rats at 2 or 6 months of age
raised at Radboud University, Nijmegen, The Netherlands.
WAG/Rij rats of 2 months of age do not show SWDs yet,
and, therefore, are considered “presymptomatic.” All 6-
month-old WAG/Rij rats have about 16-20 SWDs per hour,
or >200 SWDs per day,15 and are thus defined as “symp-
tomatic.” As control rats, we used age-matched Agouti
Copenhagen Irish (ACI) rats or age-matched Wistar rats.
ACI rats show no or only very few SWDs and the lowest
number of SWDs of all inbred strains investigated, as
assessed in a 48 h EEG evaluation study,20 and in all cases
they have much less SWDs than WAG/Rij rats of the same
age.21 However, ACI rats have a different genetic back-
ground with respect to WAG/Rij rats. Wistar rats have the
same genetic background of WAG/Rij rats, and may occa-
sionally develop SWDs or have no SWDs at all, depending
on the substrain.22,23 Rats were housed under a 12 h-12 h
light/dark cycle under standard conditions; food, water, and
cage enrichment were always available. All efforts were
done to cause as little discomfort as possible, and to use as
few animals as was considered meaningful. Ethical
approval was obtained from Ethics Committee on Animal
Key points
• Expression of the thrombospondin-1 gene is reduced
in the ventrobasal thalamus of a genetic rat model of
absence epilepsy
• This reduction precedes the onset of absence seizures,
linking thrombospondin-1 to the pathogenesis of
absence epilepsy
• Genetic variants of THBS1 (the gene encoding for
thrombospondin-1) are more frequent in patients with
IGE/GGE than in healthy controls
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Research of the Radboud University Nijmegen (RU-DEC,
‘Radboud University Dier Experimenten Commissie’). For
the analysis of Thbs1 and Cacna2d1 transcripts we per-
formed two independent experiments. In a first experiment,
we examined the two transcripts in the ventrobasal thala-
mus, somatosensory cortex, and motor cortex from WAG/
Rij and age-matched ACI rats. In a second experiment, we
measured the transcript of Thbs1 in the ventrobasal thala-
mus and somatosensory cortex in a new set of 6-month-old
WAG/Rij andWistar rats. For western blot analysis of a2d1,
Rab3A, and VGLUT1 protein levels, we compared WAG/
Rij, ACI, and Wistar rats for measurements in the ven-
trobasal thalamus, and WAG/Rij and ACI rats for measure-
ments in the somatosensory cortex.
Biochemical analysis of the principal areas of the
corticothalamocortical network
Male WAG/Rij and age-matched control ACI or Wis-
tar rats of 2 or 6 months of age were decapitated, and
brains were rapidly dissected out and frozen. The brains
from each rat were coded and codes were released after
biochemical analysis. Brains were cut coronally by a
cryostat, and tissue that comprises the principal area of
the corticothalamocortical network was dissected using
the coronal diagrams (between coordinates from bregma
– 1.88 mm and – 3.80 mm), according to Paxinos and
Watson atlas as a guide. For cortical areas, we dissected
a part of the cortex that included the primary somatosen-
sory cortex (S1) and another portion of the cortex that
included the primary motor cortex (M1). A thalamic por-
tion containing ventrobasal thalamic nuclei (VB) was
also dissected.
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total RNA was extracted from different brain regions of
the corticothalamocortical network in Trizol reagent
according to manufacturer’s protocol. The RNA was further
treated with DNase (Qiagen, Hilden, Germany) and single-
stranded complementary DNA (cDNA) was synthesized
from 2 lg of total RNA using superscript III (Invitrogen,
Carlsbad, CA, U.S.A.) and random hexamers. Real-time
polymerase chain reaction (PCR) was performed on 20 ng
of cDNA by using specific primers and Power SYBR Green
Master Mix (Applied Biosystem, Foster City, CA, U.S.A.)
on an Applied Biosystems Step-One instrument. Thermal
cycler conditions were as follows: 10 min at 95°C, 40
cycles of denaturation (15 s at 95°C), and combined anneal-
ing/extension (1 min at 60°C). Primers used were as fol-
lows: Thbs1 Forw TCGGGGCAGGAAGACTATGA and
Rev ACTGGGCAGGGTTGTAATGG; Cacna2d1 Forw
CAGCAATGCTCAGGATGTGA and Rev ATCTGT-
TATCCCCTTTGCT; and b-actin Forw GTTGACATCCG-
TAAAGACC and Rev TGGAAGGTGGACAGTGAG.
mRNA copy number of each gene analyzed was calculated
from serially diluted standard curves simultaneously ampli-
fied with the samples and normalized against b-actin copy
number. Statistical analysis was performed by two-way
analysis of variance (ANOVA) and Fisher test.
Western blot analysis
Western blot analysis was carried out in the ventrobasal
thalamus and in the somatosensory cortex dissected from
WAG/Rij and age-matched control ACI or Wistar rats, at 2
or 6 months of age (n = 6 rats per group). Tissue samples
were homogenized at 4°C in 50 mM Tris-HCl buffer, pH
7.4, containing 1 mM ethylenediaminetetraacetic acid
(EDTA), 1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 lg/ml aprotinin, 1 lg/ml pepstatin, and
1 lg/ml leupeptin. Proteins were resuspended in sodium
dodecyl sulfate (SDS)-bromophenol blue reducing buffer
with 40 lM dithiothreitol (DTT). Western blot analyses
were carried out using 8, 10, or 12% SDS polyacrylamide
gels, which were electroblotted onto immunoblot polyviny-
lidene difluoride (PVDF) membranes (BioRad, Milano,
Italy); filters were blocked overnight in TTBS (Tris-Tween-
Buffer-Saline) containing 5% bovine serum albumin (BSA)
or 5% non-fat milk. Specific rabbit polyclonal antibodies
for Rab3A (1:1000; Cell Signaling Technology, Danvers,
MA, U.S.A.), VGLUT1 (1:1,000; Cell Signaling Technol-
ogy), a2d-1 (1:200; Sigma, St. Louis, MO, U.S.A.) or mouse
monoclonal antibody for b-actin (1:100.000; Sigma) were
used. We also used four commercially available anti-throm-
bospondin-1 antibodies (1:300; Calbiochem, San Diego,
CA, U.S.A.; 1:500; Abcam, Cambridge, MA, U.S.A.;
1:500, Thermo Scientific, Rockford, IL, U.S.A.; 1:1000,
R&D Systems, Minneapolis, MN, U.S.A.). Blots were then
incubated for 1 h with secondary antibodies (peroxidase-
coupled anti-rabbit or anti-mouse, Amersham, Piscataway,
NJ, U.S.A.) diluted 1:7,000 with TTBS. Immunostaining
was revealed by enhanced chemiluminescence (ECL,
Amersham).
Patients, sequencing, and annotation of the variants
Whole-exome sequencing data from two independent
cohorts of IGE/GGE patients recruited through the Genetic
Commission of the Italian League Against Epilepsy
(LICE) and the EuroEPINOMICS-CoGIE Consortium
(Appendix 1) were analyzed. Their clinical information,
including data on EEG and antiepileptic therapy, were
recorded on data collection forms. Available charts and
investigations were reviewed by experienced neurologists
(PS, HL, PP) before making a final clinical diagnosis. Geno-
mic DNA isolation and genetic analysis was carried out with
the Nimblegen-SeqCapEZ-V244M enrichment kit on the
Illumina HiSeq2000 system as described.24,25 Only samples
with a minimum of 90% of all bases in the coding region of
the THBS1 and CACNA2D1 being covered by at least 11
reads were used and the Human Gene Mutation Database
(HGMD) variants identified in the patients were validated
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by Sanger sequencing. Variant annotation was performed
using the HGMD Professional 2013. Variant frequencies
(minor allele frequency, MAF, >1%) were obtained from
the ExAC collection (http://exac.broadinstitute.org/). Statis-
tical analysis was carried out by means of two-tailed chi-
square with Yates correction.
Results
Reduced thrombospondin-1 gene expression in the
ventrobasal thalamus in spontaneously epilepticWAG/
Rij rats
We used WAG/Rij rats at 2 and 6 months of age
(corresponding to a presymptomatic and symptomatic
age, respectively) and age-matched control ACI or Wis-
tar rats for the analysis of thrombospondin-1, a2d-1 sub-
unit, and two biochemical markers of glutamatergic
terminals, that is, Rab3A and VGLUT1. All symp-
tomatic WAG/Rij rats show a high frequency of SWDs
recorded by EEG as exemplified in Figure 1. Thbs1
mRNA levels were largely reduced in the ventrobasal
thalamus of both presymptomatic and symptomatic
WAG/Rij rats, as compared to age-matched nonepileptic
control rats (Fig. 2A). Levels did not differ between
presymptomatic and symptomatic WAG/Rij rats
(Fig. 2A), suggesting that the reduced expression of
thrombospondin-1 in the ventrobasal thalamus is not an
epiphenomenon of SWDs in WAG/Rij rats. No changes
in thrombospondin-1 mRNA levels were found in the
somatosensory and motor cortex of WAG/Rij rats at
both 2 and 6 months of age (Fig. 2A). To exclude that
the observed difference in thalamic Thbs1 mRNA levels
between WAG/Rij and ACI rats was due to the different
genetic background of the two strains of rats, we per-
formed an additional experiment in which the transcript
of Thbs1 was measured in the ventrobasal thalamus of
WAG/Rij rats and Wistar rats at 6 months of age.
Levels were significantly lower in the ventrobasal thala-
mus of WAG/Rij rats, whereas no changes were found
in the somatosensory cortex (Fig. 2B). We were unable
to measure thrombospondin-1 protein levels in brain
regions of WAG/Rij and control rats because we could
not detect a clean band, corresponding to the deduced
molecular size of thrombospondin-1 by western blot
analysis, using four commercially available anti-throm-
bospondin-1 antibodies.
In contrast to thrombospondin-1, no changes in the
transcript of Cacna2d1 were found in the ventrobasal
thalamus, somatosensory, and motor cortex of WAG/Rij
rats as compared to ACI rats (Fig. 2C). In the
somatosensory cortex, the transcript of a2d-1 showed a
trend to a reduction with age in both WAG/Rij and
ACI rats, whereas a significant increase with age was
seen in the motor cortex (Fig. 2C). Immunoblot analysis
showed no changes in a2d-1 protein levels in the ven-
trobasal thalamus of WAG/Rij rats at 2 or 6 months of
age, as compared to age-matched ACI or Wistar rats
(Fig. 3A). Knowing that thrombospondins enhance the
formation of glutamatergic synapses by interacting with
a2d-1,
12 we extended the analysis to Rab3A and
VGLUT1, which are established presynaptic markers of
glutamatergic terminals. Rab3A levels did not change
in the ventrobasal thalamus of presymptomatic and
symptomatic WAG/Rij rats, as compared to ACI or
Wistar rats (Fig. 3B). In contrast, there was a signifi-
cant strain- and age-related reduction (but not strain 9
age difference) of VGLUT1 in the ventrobasal thalamus
of WAG/Rij rats as compared to ACI or Wistar rats
(Fig. 3C). No changes in a2d-1, Rab3A, or VGLUT1
protein levels were found in the somatosensory cortex
of WAG/Rij rats as compared to age-matched ACI rats
(Fig. 3D–F).
Genetic variants in the THBS1 gene encoding for
thrombospondin-1 are more frequent in IGE/GGE
patients
Overall, 238 patients affected by IGE/GGE were
included in the analysis (Table S1). One hundred forty-
three patients were affected by childhood absence epilepsy
(CAE); 21 patients by juvenile absence epilepsy (JAE); 47
patients by juvenile myoclonic epilepsy (JME); and 27
patients by generalized tonic–clonic seizures alone
(EGTC). All subjects were of European descent (Italian
128, German 54, Finnish 22, Dutch 11, British 9, Danish
8, Turkish 6). The cohort included 138 female subjects
(58%). Age at epilepsy onset ranged from 5 years to
38 years, with a median of 8 years. Most of cases
(n = 183) derived from multiplex families with at least
two affected family members. Most of the patients
(n = 189; 79.4%) were treated with one antiseizure drug,
usually valproate or levetiracetam.
In this cohort, we identified a total of 11 variants (8 dis-
tinct HGMD missense mutations in THBS1 and 3 in CAC-
NA2D1) in the whole IGE/GGE cohort (total
frequency = 4.62%). Details of the identified variants and
their frequency are reported in Table 1. Variants in THBS1
were enriched in the IGE/GGE cohort (8/238; 3.36%) com-
pared with control population (1829/121,230; 1.5%)
Figure 1.
EEG recording showing a typical SWD in symptomatic 6-month-
oldWAG/Rij rats.
Epilepsia ILAE
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(p = 0.03). In contrast, variants in CACNA2D1 were not
more frequent in patients (3/238; 1.26%) than in control
populations (733/120,817; 0.6%) (p = 0.37) (Table 2).
Syndrome subdivision analysis failed to demonstrate that
variants in both genes were specifically enriched in CAE
syndrome (Table S2).
Figure 2.
Reduced Thbs1 transcript in the ventrobasal thalamus of WAG/Rij rats. mRNA levels of Thbs1 in the ventrobasal thalamus, somatosen-
sory cortex, and motor cortex of WAG/Rij and ACI rats at 2 and 6 months of age are shown in (A). mRNA levels of Thbs1 in the ven-
trobasal thalamus and somatosensory cortex of 6-month-old WAG/Rij rats and age-matchedWistar rats are shown in (B). mRNA levels
of Cacna2d1 in the ventrobasal thalamus, somatosensory cortex, and motor cortex of WAG/Rij and ACI rats at 2 and 6 months of age
are shown in (C). In (A) and (C), and (B), values are means  standard error of the mean (SEM) of 4-5, and 6 animals per group, respec-
tively. In (A), a strain effect for the thalamus was found (two-way ANOVA: F1,15 = 45.65, WAG/Rij < ACI); post hoc test (Fisher’s Least
Significant Difference, LSD) confirmed that this strain effect was present for both 2 and 6 months groups * p < 0.05. In (B), (Student’s t
test, t10 = 6.81, *p < 0.05) strain difference in thalamus: 6-month-old WAG/Rij < age-matched Wistar rats. In (C), age effect in motor
cortex *p < 0.05 (two-way ANOVA, F1,13 = 6.56, older < younger rats); post hoc test (Fisher’s LSD) confirmed that this age effect was
present in both strains *p < 0.05.
Epilepsia ILAE
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Discussion
Thrombospondin-1, one of the five members of the
thrombospondin family, is widely expressed in the organism
and is known to regulate fundamental cell biologic pro-
cesses, such as cell attachment to extracellular matrix,
cytoskeletal dynamics, and cell migration. In the developing
CNS, astrocyte-secreted thrombospondin-1 promotes
synaptogenesis, neuronal migration, and axonal
growth.13,26–29 The demonstration that thrombospondin-1
interacts with the a2d-1 subunit to stimulate the formation
of excitatory synapses12 raised interest on the potential role
of thrombospondin-1 in disorders that are targeted by a2d
ligands, such as neuropathic pain and epilepsy. Several lines
of evidence suggest that an abnormal synaptogenesis con-
tributes to epileptogenesis, that is, to the process by which
the brain develops epilepsy. Accordingly, temporal lobe
epilepsy in patients and pilocarpine-induced epilepsy in rats
are associated with an increased hippocampal and cortical
expression of ephrinB3 and its receptor EphB3, which play
a key role in synaptogenesis and mechanisms of synaptic
reorganization and plasticity.30 Other proteins that regulate
synaptogenesis, such as synapsin II and synaptophysin, have
been also implicated in the pathophysiology of epi-
lepsy.31,32 Of interest, matrix metalloproteinases (MMPs),
which cleave extracellular matrix (EM) proteins and regu-
late synaptogenesis, have an active role in epileptogenesis
in different experimental animal models,33 and the EM pro-
tein, SC1, translocates from neuronal cell bodies to excita-
tory nerve terminals following status epilepticus in the rat
lithium-pilocarpine model.34
Recent evidence suggests that thrombospondin-1, by pro-
moting the formation of new excitatory synapses, con-
tributes to the development of a hyperexcitable neuronal
network, which is a critical event in epilepsy. Mendus
et al.35 have found that mice lacking thrombospondin-1 or
Figure 3.
Reduced VGLUT1 protein levels in the ventrobasal thalamus ofWAG/Rij rats. Western blot analysis of a2d-1, Rab3A, and VGLUT1 in the
ventrobasal thalamus of presymptomatic and symptomatic WAG/Rij rats and age-matched ACI orWistar rats are shown in (A), (B), and
(C), respectively. Representative immunoblots from three rats per group are shown. Densitometric values are means  SEM of six rats
per group. In (C), two-way ANOVA shows a significant strain effect (F2,30 = 7.15; p < 0.05) and age effect (F1,30 = 4.18; p < 0.05), but no
strain9 age interaction effect (F2,30 = 0.27; n.s.). p < 0.05 vs. 2-month-old ACI rats (*) or vs. 6-month-old ACI andWistar rats (#).Wes-
tern blot analysis of a2d-1, Rab3A, and VGLUT1 in the somatosensory cortex of presymptomatic and symptomatic WAG/Rij rats and
age-matched ACI rats are shown in (D), (E), and (F), respectively (densitometric values are means SEM of 6 rats per group).
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thrombospondins 1 and 2 were more sensitive to
pentylenetetrazole kindling. These mice also showed a
reduced expression of a2d-1/2 protein levels in the cortex,
suggesting that the thrombospondin/a2d axis is a key regula-
tor of susceptibility to seizures.35 The importance of the
thrombospondin/a2d axis in the pathophysiology of epi-
lepsy is supported by the evidence that mice overexpressing
a2d-1 show epileptiform activity and behavioral arrests
associated with an increased number of excitatory synapses
in the cortex.36
Here, we showed for the first time that expression of the
Thbs1 gene encoding for thrombospondin-1 was substan-
tially reduced in the ventrobasal thalamus of WAG/Rij rats,
which represent an established genetic animal model of
spontaneous absence epilepsy.15,16 Remarkably, a large
reduction in Thbs1 mRNA levels was observed both in
presymptomatic and symptomatic WAG/Rij rats, suggest-
ing that a reduced production of thrombospondin-1 in the
thalamus was not secondary to the occurrence of SWDs in
the corticothalamocortical network underlying absence sei-
zures. As opposed to mice lacking thrombospondin-1,35 we
did not detect changes in a2d-1 mRNA and protein levels
associated with the reduction of thrombospondin-1 in
WAG/Rij rats. In contrast, WAG/Rij rats showed lowered
VGLUT1 levels in the thalamus with respect to nonepileptic
control rats, suggesting that the reduced expression of Thbs1
gene might have caused an impaired formation of excitatory
synapses in the thalamus ofWAG/Rij rats.
No changes in THBS-1 gene expression or VGLUT1
protein levels were found in the site of origin of the
SWDs, the somatosensory cortex, suggesting that a possi-
ble defect in thalamic synaptogenesis combines with a
cortical generator in the pathophysiology of absence sei-
zures. The relevance of a defective synaptogenesis in the
pathophysiology of absence seizures is supported by the
evidence that stargazer mice, which show absence sei-
zures, are characterized by an impairment of synaptic for-
mation in the cerebellum,37 which exerts a modulatory
role on generalized SWDs through the firing of deep cere-
bellar nuclei.38,39 Double mutant zi/zi, tm/tm rats, which
represent another rat model of spontaneous absence epi-
lepsy, show a reduced expression of the synaptic vesicle
proteins, SV2A and synaptotagmin-1.40 A thalamic defect
of excitatory synapses may reinforce the hyperpolarizing
milieu generated by c-aminobutyric acid (GABA)
released from neurons of the reticular thalamus, thereby
facilitating the recovery of T channels from inactivation
in ventrobasal thalamic neurons, which ultimately results
into pathologic oscillations of the corticothalamocortical
network.3 This hypothesis warrants further investigation.
Nevertheless, the suggestion that a defect of excitatory
neurotransmission is involved in the pathophysiology of
absence seizures is supported by the evidence that two
types of glutamate receptors, the mGlu1 and mGlu5 meta-
botropic glutamate receptors, are downregulated in the
Table 1. Summary of THBS1 and CACNA2D1 variants identified in the IGE/GGE cohort and their frequency from the
ExAC collection
Gene Genomic position
Protein
change MAF
No. minor allele/
No. total alleles MAF in Europeans
No. minor allele/
No. total alleles
in Europeans
THBS1 15:39874505 G/A p.R60H 0.00004949 6/121,230 0.0000152 1/66,600
THBS1 15:39874642 G/T p.A106S NA NA NA NA
THBS1 15:39874742 A/G p.H139R 0.0001324 16/120,830 0.0001355 9/66,438
THBS1 15:39874918 C/T p.R198C 0.00003462 4/115,536 0.0000313 2/63,914
THBS1 15:39883456 G/A p.R773H 0.0001483 18/121,366 0 0/66,698
THBS1 15:39883721 G/A p.R810Q 0.00002472 3/121,378 0.00002998 2/66,712
THBS1 15:39884907 G/A p.G891R NA NA NA NA
THBS1 15:39886304 G/A p.R1091H 0.0001925 21/109,102 0.0002008 12/59,768
CACNA2D1 7:81588616 T/G p.D1045A 0.002805 339/120,840 0.004544 302/66,464
CACNA2D1 7:81599241 C/G p.S755T 0.0007741 93/120,134 0.001209 80/66,170
CACNA2D1 7:81601108 C/T p.S709N 0.00269 324/120,468 0.004103 272/66,300
MAF, Minor allele frequency. For ExAC collection, see http://exac.broadinstitute.org/
Table 2. Statistical analysis of THBS1 andCACNA2D1
variants observed in patients affected by IGE/GGE and in
subjects from the ExAC collection
Patients ExAC collection Total
THBS1
Mutated 8 1829 1837
Wild-type 230 121,183 121,413
Total 238 121,230 123,250
% of mutated 3.36 1.5 p = 0.03*
CACNA2D1
Mutated 3 733 736
Wild-type 235 120,084 120,319
Total 238 120,817 121,055
% of mutated 1.26 0.6 p = 0.37*
*Two-tailed chi-square with Yates correction. For ExAC collection, see
http://exac.broadinstitute.org/
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ventrobasal thalamus of symptomatic WAG/Rij rats, and
pharmacologic activation of either mGlu1 or mGlu5
receptors reduces the frequency of SWDs.41,42
IGE/GGEs are the most common types of inherited epi-
lepsy and include at least four well-established epilepsy
syndromes, namely, CAE, JAE, JME, and EGTC, all of
them characterized by the presence of SWDs/polyspikes.43
Despite its high heritability of 80%, the genetic background
is still largely unknown.44
To assess the potential impact of thrombospondin and the
a2d-1 subunit in the pathophysiology of absence epilepsy in
humans, we checked a large cohort of patients affected by
IGE/GGE. This analysis revealed that genetic variants of
THBS1 were significantly more frequent in patients affected
by IGE/GGE than in nonepileptic controls, whereas the fre-
quency of CACNA2D1 was unchanged. Syndromic stratifi-
cation analysis failed to show that variants in both genes
were specifically enriched in any of the IGE/GGE syn-
dromes, including CAE, which is in line with the view that
IGE/GGE is a spectrum of epilepsy syndromes with variable
age at onset associated with common EEG traits generated
by pathologic oscillations in a corticothalamocortical net-
work with a cortical origin.3
In conclusion, we showed that expression of throm-
bospondin-1 gene is reduced in the ventrobasal thalamus of
WAG/Rij rats, which model absence epilepsy in humans.
This reduction precedes the onset of absence seizures, link-
ing thrombospondin-1 to the pathogenesis of absence epi-
lepsy in WAG/Rij rats. Moreover, a potential role for
thromospondin-1 in the pathogenesis of generalized epi-
lepsy is supported by the finding that polymorphic variants
of the THBS1 gene showed a much higher frequency in a
large cohort of patients affected by IGE/GGE compared to
control population, although the increase was not significant
in the subcohort of patients affected by CAE. Overall these
findings support the hypothesis that the thrombospondin-1/
a2d-1 axis is involved in the pathophysiology of epilepsy
and encourage further studies on the potential relationship
between thrombospondin-1-regulated synaptic formation
and epileptogenesis within the corticothalamocortical
network.
Disclosure
None of the authors has any conflict of interest to disclose. We confirm
that we have read the Journal’s position on issues involved in ethical publi-
cation and affirm that this report is consistent with those guidelines.
References
1. Meeren HK, Pijn JP, Van Luijtelaar EL, et al. Cortical focus drives
widespread corticothalamic networks during spontaneous absence sei-
zures in rats. J Neurosci 2002;22:1480–1495.
2. Polack PO, Guillemain I, Hu E, et al. Deep layer somatosensory corti-
cal neurons initiate spike-and-wave discharges in a genetic model of
absence seizures. J Neurosci 2007;27:6590–6599.
3. Blumenfeld H. Cellular and network mechanisms of spike-wave
seizures. Epilepsia 2005;46:21–33.
4. Polack PO, Charpier S. Ethosuximide converts ictogenic neurons
initiating absence seizures into normal neurons in a genetic model.
Epilepsia 2009;50:1816–1820.
5. Vartanian MG, Radulovic LL, Kinsora JJ, et al. Activity profile of
pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res
2006;68:189–205.
6. Thomas P, Valton L, Genton P. Absence and myoclonic status epilep-
ticus precipitated by antiepileptic drugs in idiopathic generalized
epilepsy. Brain 2006;129:1281–1292.
7. Zamponi GW. Targeting voltage-gated calcium channels in neurologi-
cal and psychiatric diseases.Nat Rev Drug Discov 2016;15:19–34.
8. Dolphin AC, Wyatt CN, Richards J, et al. The effect of alpha2-delta
and other accessory subunits on expression and properties of the cal-
cium channel alpha1G. J Physiol 1999;519:35–45.
9. Dubel SJ, Altier C, Chaumont S, et al. Plasma membrane expression of
T-type calcium channel alpha(1) subunits is modulated by high volt-
age-activated auxiliary subunits. J Biol Chem 2004;279:29263–29269.
10. Lacinova L, Klugbauer N. Modulation of gating currents of the Ca(v)
3.1 calcium channel by alpha 2 delta 2 and gamma 5 subunits. Arch
Biochem Biophys 2004;425:207–213.
11. Lacinova L, Klugbauer N, Hofmann F. Absence of modulation of the
expressed calcium channel alpha1G subunit by alpha2delta subunits. J
Physiol 1999;516:639–645.
12. Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor alpha2-
delta-1 is a neuronal thrombospondin receptor responsible for excita-
tory CNS synaptogenesis.Cell 2009;139:380–392.
13. Christopherson KS, Ullian EM, Stokes CC, et al. Thrombospondins
are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell
2005;120:421–433.
14. Liauw J, Hoang S, Choi M, et al. Thrombospondins 1 and 2 are neces-
sary for synaptic plasticity and functional recovery after stroke. J
Cereb Blood FlowMetab 2008;28:1722–1732.
15. van Luijtelaar EL, Coenen AM. Two types of electrocortical parox-
ysms in an inbred strain of rats.Neurosci Lett 1986;70:393–397.
16. van Luijtelaar G, Sitnikova E, L€uttjohann A. On the origin and sudden-
ness of absences in genetic absence models. Clin EEG Neurosci
2011;42:83–97.
17. Peeters BW, van Rijn CM, Vossen JM, et al. Effects of GABA-
ergic agents on spontaneous non-convulsive epilepsy, EEG and
behaviour, in the WAG/RIJ inbred strain of rats. Life Sci
1989;45:1171–1176.
18. Coenen AM, Blezer EH, van Luijtelaar EL. Effects of the GABAup-
take inhibitor tiagabine on electroencephalogram, spike-wave dis-
charges and behaviour of rats. Epilepsy Res 1995;21:89–94.
19. Bouwman BM, Suffczynski P, Midzyanovskaya IS, et al. The effects
of vigabatrin on spike and wave discharges in WAG/Rij rats. Epilepsy
Res 2007;76:34–40.
20. Inoue M, Peeters BW, van Luijtelaar EL, et al. Spontaneous occur-
rence of spike-wave discharges in five inbred strains of rats. Physiol
Behav 1990;48:199–201.
21. Schridde U, van Luijtelaar G. The influence of strain and housing on
two types of spike-wave discharges in rats. Genes Brain Behav
2004;3:1–7.
22. Willoughby JO, Mackenzie L. Nonconvulsive electrocorticographic
paroxysms (absence epilepsy) in rat strains. Lab Anim Sci
1992;42:551–554.
23. Shaw FZ. 7-12 Hz high-voltage rhythmic spike discharges in rats eval-
uated by antiepileptic drugs and flicker stimulation. J Neurophysiol
2007;97:238–247.
24. Galizia EC, Myers CT, Leu C, et al. CHD2 variants are a risk factor for
photosensitivity in epilepsy. Brain 2015;138:1198–1207.
25. Lal D, Reinthaler EM, Dejanovic B, et al. Evaluation of presumably
disease causing SCN1A variants in a cohort of common epilepsy syn-
dromes. PLoS ONE 2016;11:e0150426.
26. Xu J, Xiao N, Xia J. Thrombospondin 1 accelerates synaptogenesis in
hippocampal neurons through neuroligin 1. Nat Neurosci 2010;13:22–
24.
27. Iruela-Arispe ML, Liska DJ, Sage EH, et al. Differential expression of
thrombospondin 1, 2, and 3 during murine development. Dev Dyn
1993;197:40–56.
Epilepsia, 58(11):1993–2001, 2017
doi: 10.1111/epi.13898
2000
I. Santolini et al.
28. Yu K, Ge J, Summers JB, et al. TSP-1 secreted by bone marrow stro-
mal cells contributes to retinal ganglion cell neurite outgrowth and sur-
vival. PLoS ONE 2008;3:e2470.
29. Cahoy JD, Emery B, Kaushal A, et al. A transcriptome database for
astrocytes, neurons, and oligodendrocytes: a new resource for under-
standing brain development and function. J Neurosci 2008;28:264–
278.
30. Huang H, Li R, Yuan J, et al. Up-regulated ephrinB3/EphB3 expres-
sion in intractable temporal lobe epilepsy patients and pilocarpine
induced experimental epilepsy rat model. Brain Res 2016;1639:1–12.
31. Chen LS, Wong JG, Banerjee PK, et al. Kainic acid-induced focal cor-
tical seizure is associated with an increase of synaptophysin immunore-
activity in the cortex. Exp Neurol 1996;141:25–31.
32. Prasad DK, Shaheen U, Satyanarayana U, et al. Association of
GABRA6 1519 T>C (rs3219151) and Synapsin II (rs37733634) gene
polymorphisms with the development of idiopathic generalized epi-
lepsy. Epilepsy Res 2014;108:1267–1273.
33. Mizoguchi H, Yamada K. Roles of matrix metalloproteinases and their
targets in epileptogenesis and seizures. Clin Psychopharmacol Neu-
rosci 2013;11:45–52.
34. Lively S, Brown IR. The extracellular matrix protein SC1/hevin local-
izes to excitatory synapses following status epilepticus in the rat
lithium-pilocarpine seizure model. J Neurosci Res 2008;86:2895–
2905.
35. Mendus D, Rankin-Gee EK, Mustapha M, et al. Increased sensitivity
to kindling in mice lacking TSP1.Neuroscience 2015;305:302–308.
36. Faria LC, Gu F, Parada I, et al. Epileptiform activity and behavioral
arrests in mice overexpressing the calcium channel subunit a2d-1.Neu-
robiol Dis 2017;102:70–80.
37. Meng H, Walker N, Su Y, et al. Stargazin mutation impairs cerebellar
synaptogenesis, synaptic maturation and synaptic protein distribution.
Brain Res 2006;1124:197–207.
38. Kros L, Eelkman Rooda OH, Spanke JK, et al. Cerebellar output con-
trols generalized spike-and-wave discharge occurrence. Ann Neurol
2015;77:1027–1049.
39. Kros L, Rooda OH, De Zeeuw CI, et al. Controlling cerebellar output
to treat refractory epilepsy. Trends Neurosci 2015;38:787–799.
40. Hanaya R, Hosoyama H, Sugata S, et al. Low distribution of synaptic
vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hip-
pocampus of spontaneously epileptic rats exhibiting both tonic convul-
sion and absence seizure.Neuroscience 2012;221:12–20.
41. Ngomba RT, Santolini I, Biagioni F, et al. Protective role for type-1
metabotropic glutamate receptors against spike and wave discharges in
the WAG/Rij rat model of absence epilepsy. Neuropharmacology
2011;60:1281–1291.
42. D’Amore V, Santolini I, van Rijn CM, et al. Potentiation of mGlu5
receptors with the novel enhancer, VU0360172, reduces spontaneous
absence seizures in WAG/Rij rats. Neuropharmacology 2013;66:330–
338.
43. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the
epilepsies: position paper of the ILAE commission for classification
and terminology. Epilepsia 2017;58:512–521.
44. International League Against Epilepsy Consortium on Complex
Epilepsies. Genetic determinants of common epilepsies: a meta-analy-
sis of genome-wide association studies. Lancet Neurol 2014;13:893–
903.
Appendix 1
EuroEPINOMICS CoGIE Consortium
Aarno Palotie, Wellcome Trust Sanger Institute, Wellcome Trust Gen-
ome Campus, Hinxton, Cambridgeshire, United Kingdom; Institute for
Molecular Medicine Finland, University of Helsinki, Helsinki, Finland;
Program in Medical and Population Genetics and Genetic Analysis Plat-
form, The Broad Institute of MIT and Harvard, Cambridge, MA, U.S.A.;
Anna-Elina Lehesjoki Folkh€alsan, Institute of Genetics, Helsinki, Finland;
Research Programs Unit, Molecular Neurology, University of Helsinki,
Helsinki, Finland; Neuroscience Center, University of Helsinki, Helsinki,
Finland; Ann-Kathrin Ruppert, Cologne Center for Genomics, University
of Cologne, Cologne, Germany; Auli Siren, Outpatient Clinic for Persons
with Intellectual Disability, Tampere University Hospital, Tampere, Fin-
land; Bobby Koeleman, Department of Medical Genetics, Division of
Biomedical Genetics, University Medical Center Utrecht, Utrecht, The
Netherlands; Dennis Lal, Cologne Center for Genomics, University of
Cologne, Cologne, Germany; Felicitas Becker, Department of Neurology
and Epileptology, Hertie Institute for Clinical Brain Research, University
of Tubingen, Tubingen, Germany; Hande Caglayan, Department of Molec-
ular Biology and Genetics, Bogazici University, Istanbul, Turkey; Helle
Hjalgrim, Danish Epilepsy Centre, Dianalund, Denmark Institute for
Regional Health Services, University of Southern Denmark, Odense, Den-
mark; Hiltrud Muhle, University Medical Center Schleswig-Holstein,
Christian-Albrechts University, Kiel, Germany; Holger Thiele, Cologne
Center for Genomics, University of Cologne, Cologne, Germany; Ingo Hel-
big, University Medical Center Schleswig-Holstein, Christian-Albrechts
University, Kiel, Germany; Janine Altmuller, Cologne Center for Geno-
mics, University of Cologne, Cologne, Germany; Kamel Jabbari, Cologne
Center for Genomics, University of Cologne, Cologne, Germany; Kate
Everett, Human Genetics Research Centre, St. George’s University of Lon-
don, London, United Kingdom; Patrick May, Luxembourg Centre for Sys-
tems Biomedicine, University of Luxembourg, Esch-sur-Alzette,
Luxembourg; Peter Nurnberg, Cologne Center for Genomics, University of
Cologne, Cologne, Germany; Center for Molecular Medicine Cologne
(CMMC), University of Cologne, Cologne, Germany; Cologne Excellence
Cluster on Cellular Stress Responses in Aging-Associated Diseases
(CECAD), University of Cologne, Cologne, Germany; Rikke Møller, Dan-
ish Epilepsy Centre, Dianalund, Denmark; Institute for Regional Health
Services, University of Southern Denmark, Odense, Denmark; Rima Nab-
bout, Centre de Reference Epilepsies Rares, Inserm U1129, Neuropedi-
atrics Department, Necker-Enfants Malades Hospital, APHP, Paris
Descartes University, CEA, Orsay, France; Roland Krause, Luxembourg
Center for Systems Biomedicine, University of Luxembourg, Esch-sur-
Alzette, Luxembourg; Rudi Balling, Luxembourg Centre for Systems
Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg;
Stephanie Baulac, Institut National de la Sante et de la Recherche Medicale
U975, Centre de Recherche de l’Institut du Cerveau et de la Moelle Epi-
nie`re, Hoˆ pital Pitie-Salpe^triere, Paris, France; Centre National de la
Recherche Scientifique, Paris, France; Universite Pierre et Marie Curie
(Paris VI), UMR_S 975, Paris, France; Thomas Sander, Cologne Center for
Genomics, University of Cologne, Cologne, Germany; Wolfram Kunz
Department of Epileptology and Life & Brain Center, University of Bonn
Medical Center, Bonn, Germany; Yvonne Weber, Department of Neurol-
ogy and Epileptology, Hertie Institute for Clinical Brain Research, Univer-
sity of Tubingen, Tubingen, Germany.
Collaborative Group of Italian League Against
Epilepsy (LICE) Genetic Commission
Amedeo Bianchi, Angela La Neve, Antonietta Coppola, Salvatore Stri-
ano, Giuseppe Capovilla, Edoardo Ferlazzo, Irene Bagnasco, Alessandro
Ferretti, Pasquale Parisi, Carlo Di Bonaventura, Maria Stella Vari, Fran-
cesca Pinto, Francesca Bisulli, Paolo Tinuper, CarloMinetti, Vincenzo Bel-
castro, Lucio Giordano, Antonio Gambardella.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Clinical data overview of the investigated IGE/
GGE cohort.
Table S2. Statistical analysis of THBS1 and CACNA2D1
variants observed in CAE patients and in controls from the
ExAC collection (http://exac.broadinstitute.org/).
Epilepsia, 58(11):1993–2001, 2017
doi: 10.1111/epi.13898
2001
Thrombospondin-1 and Absence Epilepsy
